ArticleQuantitative biology (Beijing, China)2023
Pattern discovery of long non-coding RNAs associated with the herbal treatments in breast and prostate cancers.
Article in Quantitative biology (Beijing, China), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pattern discovery of long non-coding RNAs associated with the herbal treatments in breast and prostate cancers.Quantitative biology (Beijing, China) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functionally characterized lncRNAs play critical roles in cancer progression but the potential relationship between lncRNAs and herbal medicine is yet to be known. To identify this association by RNA-seq data for breast and prostate cancer, a co-expression network in response to herbal medicines was performed. GO terms and pathway analyses on differential co-expressed mRNAs revealed that lncRNAs were widely co-expressed with metabolic process genes. On the other hand, various machine learning-based prediction systems on the differential co-expressed lncRNAs were implemented. Results show that the Deep Learning model could accurately forecast cancer-related lncRNAs. Background: Accumulating evidence shows that long non-coding RNAs (lncRNAs) play critical roles in cancer progression. The possible association between lncRNAs and herbal medicine is yet to be known. This study aims to identify medicinal herbs associated with lncRNAs by RNA-seq data for breast and prostate cancer. Methods: To develop the optimal approach for identifying cancer-related lncRNAs, we implemented two steps: (1) applying protein-protein interaction (PPI), Gene Ontology (GO), and pathway analyses, and (2) applying attribute weighting and finding the efficient classification model of the machine learning approach. Results: In the first step, GO terms and pathway analyses on differential co-expressed mRNAs revealed that lncRNAs were widely co-expressed with metabolic process genes. We identified two hub lncRNA-mRNA networks that implicate lncRNAs associated with breast and prostate cancer. In the second step, we implemented various machine learning-based prediction systems (Decision Tree, Random Forest, Deep Learning, and Gradient-Boosted Tree) on the non-transformed and Z-standardized differential co-expressed lncRNAs. Based on five-fold cross-validation, we obtained high accuracy (91.11%), high sensitivity (88.33%), and high specificity (93.33%) in Deep Learning which reinforces the biomarker power of identified lncRNAs in this study. As data originally came from different cell lines at different durations of herbal treatment intervention, we applied seven attribute weighting algorithms to check the effects of variables on identifying lncRNAs. Attribute weighting results showed that the cell line and time had little or no effect on the selected lncRNAs list. Besides, we identified one known lncRNAs, downregulated RNA in cancer (DRAIC), as an essential feature. Conclusions: This study will provide further insights to investigate the potential therapeutic and prognostic targets for prostate cancer (PC) and breast cancer (BC) in common.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.